Brad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.
Brad Kahl, MD
Advertisement
Articles by Brad Kahl, MD
Advertisement
Latest Updated Articles
Treating Patients With Indolent Lymphomas in the Relapsed SettingPublished: March 27th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
